Hikma Pharmaceuticals PLC hit a new 52-week high, surpassing its previous peak of £23.14, which the company achieved on ...

For example, the Hikma Pharmaceuticals PLC (LON:HIK) share price is up 23% in the last 5 years, clearly besting the market return of around 3.1% (ignoring dividends). However, more recent returns ...

PLC (LSE: HIK), a global pharmaceutical company, is set to announce its financial results for the year ending December 31, 2024, on Wednesday, February 26, 2025. The company will make a recording of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The U.S. Food and Drug Administration ...

2025 The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.